What is Aobiome?
Aobiome is dedicated to developing novel therapeutics for inflammatory conditions and central nervous system disorders by leveraging its proprietary Ammonia Oxidizing Bacteria (AOB) technology. This unique approach aims to restore essential biological processes, addressing unmet clinical needs across a spectrum of diseases. The company's current clinical programs target dermatological conditions such as acne, eczema, and rosacea, alongside hypertension. Furthermore, Aobiome is actively pursuing preclinical development for pulmonary and gastrointestinal disorders, positioning itself as a key innovator in microbiome-based medicine.
How much funding has Aobiome raised?
Aobiome has raised a total of $33.7M across 4 funding rounds:
Private Equity
$630K
Private Equity
$576K
Private Equity
$2.5M
Private Equity
$30M
Private Equity (2013): $630K, investors not publicly disclosed
Private Equity (2014): $576K, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Private Equity (2017): $30M featuring iCarbonX
Key Investors in Aobiome
iCarbonX
Digital health pioneer iCarbonX is creating the new global standard for health, wellness and healthcare by building the platform for digitizing, analyzing, and understanding life. With breakthrough technologies, deep multi-omics, artificial intelligence and experiential data, it delivers products, services and solutions for both partners and consumers to help people optimize their lives, from wellness, skincare, and fitness, to health, nutrition and prevention, to health care, condition management and outcome achievement.
What's next for Aobiome?
With the recent major strategic investment, Aobiome is poised for significant expansion and advancement of its therapeutic candidates. This substantial backing is expected to fuel the progression of its ongoing clinical trials and accelerate the development of its preclinical pipeline. The company's focus on addressing complex health issues through microbiome modulation suggests a strategic direction towards becoming a leader in this burgeoning field. Future growth will likely involve scaling operations, further clinical validation, and potentially forging strategic partnerships to bring its innovative treatments to market.
See full Aobiome company page
